A staff report by two House committees points to alleged irregularities in the Food and Drug Administration's approval of the Alzheimer's drug Aduhelm. "The High Price of Aduhelm's Approval: An ...

Aduhelm’s annual list price would be cost-effective at $3,000 to $8,400, a range representing a 85-95 percent discount from its current $56,000 annual price, the Institute for Clinical and Economic ...

Biogen is pulling the plug on the controversial drug Aduhelm, the first drug cleared by government health officials for treating Alzheimer's in nearly two decades. The pharmaceutical giant is ...

Biogen is abandoning its lackluster Alzheimer’s disease drug, Aduhelm. The Massachusetts-based company announced Wednesday that it is pulling the medication from the market following poor sales and ...

Add Yahoo as a preferred source to see more of our stories on Google. Biogen will return the rights to Aduhelm to Neurimmune, the private firm that invented it, the company said. Photo by MART ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The Kaiser Family Foundation estimates that Aduhelm will inflict significant costs on Medicaid as it covers the Alzheimer’s treatment. In a July 13 report, the foundation claimed that with a 23.1 ...

The long and tumultuous journey of Aduhelm has come to an end. Biogen announced Wednesday morning that it is relinquishing the controversial Alzheimer’s drug. Biogen said it will terminate development ...

Three papers published as Viewpoints in JAMA Internal Medicine this week highlight the rationale provided by the US Food and Drug Administration (FDA) on the agency’s approval of aducanumab (Aduhelm; ...

The review leading to the 2021 approval of Alzheimer’s med Aduhelm was “rife with irregularities,” multiple congressional committees found in an investigative report issued as the Food and Drug ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...